医生介绍

张海伟，药理学博士，副研究员，硕士生导师。中国抗癌协会肿瘤标志委员会遗传肿瘤标志协作组秘书，主要从事肿瘤个体化用药分子检测和临床咨询工作，研究方向为肿瘤分子药理，目前主持省部级课题5项，已结题3项，发表文章总影响因子为62.8，总引用次数466次，Oncogene，Euro Pharma J等杂志同行评议人。

教育经历：
2005/09 - 2010/06, 中国药科大学，药学院，博士；导师：郭青龙
2007/05 – 2010/03，清华大学，医学院，博士生；导师：常智杰
2001/09 – 2005/06，中国药科大学，药学院，本科
科研与学术工作经历：
2017/3-2018/3, 德克萨斯大学休斯顿健康医学中心, 整合生物化学和药学院, 访问****
2012/07 - 至今，重庆市肿瘤研究所，肿瘤实验室，副研究员
2011/09-2012/06，东南大学医学院，博士后，合作导师：陈宝安
2010/07 - 2012/06，中国药科大学，药学院生理教研室，讲师
2007/05 – 2010/03，清华大学，医学院，博士生
主持或参加科研项目（课题）及人才计划项目情况（按时间倒序排序）：
1. 重庆市自然基金，cstc2017jxjl0164, lncRNA CTB在汉黄芩素逆转阿霉素耐药中的作用机制研究，2017/12-2019/12, 10万元，主持
2. 重庆市自然基金，cstc2016jcyjA0107，lncRNA CTB在监测乳腺癌新辅助化疗TA方案疗效中作用及机制研究，2016/03-2018/06,5万元，主持
3. 重庆市自然基金，cstc2013jcyjA1513，汉黄芩素通过调节CDKs影响人肿瘤细胞周期机制研究 2013/03-2016/03，8万元，在研，主持
4. 江苏省自然基金，BK**，基于调控细胞内氧化还原系统的FV-429诱导肿瘤细胞死亡的机制研究，2011.12-2014.12，5万元，已结题，主持
5. 国家自然科学基金，**，控WNT信号通路逆转脑胶质瘤干细胞耐药的作用机制研究，2013/01-2015/12，20万元，已结题，参加
代表性研究成果和学术奖励情况
一、期刊论文
1. 第一作者论文
(1) H. Zhang, Y. Zhang, S.S. Ng, F. Ren, Y. Wang, Y. Duan, L. Chen, Y. Zhai, Q. Guo*, Z. Chang*, Dishevelled-DEP domain interacting protein (DDIP) inhibits Wnt signaling by promoting TCF4 degradation and disrupting the TCF4/beta-catenin complex, Cell Signal, 2010, 22:1753-1760.
(2) Zhang H, Chen F, He Y et al. Sensitivity of non-small cell lung cancer to erlotinib is regulated by the Notch/miR-223/FBXW7 pathway. Bioscience reports 2017; 37.
(3) Zhang H, Ge C, Lin C, et al. Combination of icotinib and wogonin induces apoptosis and autophagy to overcome acquired resistance in lung cancer harbouring EGFR T790M mutation[J]. International Journal of Clinical & Experimental Medicine, 2017, 10(5):7553-7562.
(4) Zhang H W, Wang E W, Li L X, et al. A regulatory loop involving miR-29c and Sp1 elevates the TGF-β1 mediated epithelial-to-mesenchymal transition in lung cancer[J]. Oncotarget, 2016, 7(52):85905.
(5) H.W. Zhang, Y. Yang, K. Zhang, L. Qiang, L. Yang, Y. Hu, X.T. Wang, Q.D. You*, Q.L. Guo*, Wogonin induced differentiation and G1 phase arrest of human U-937 leukemia cells via PKCdelta phosphorylation. Eur J Pharmacol, 2008, 591:7-12.
(6) H. Zhang, Y. Zhang, S.S. Ng, F. Ren, Y. Wang, Y. Duan, L. Chen, Y. Zhai, Q. Guo*, Z. Chang*, Dishevelled-DEP domain interacting protein (DDIP) inhibits Wnt signaling by promoting TCF4 degradation and disrupting the TCF4/beta-catenin complex, Cell Signal, 2010, 22:1753-1760.
2. 既非第一作者又非通讯作者论文
(1) J. Yu, Q.L. Guo, Q.D. You, L. Zhao, H.Y. Gu, Y. Yang, H.W. Zhang, Z. Tan, X. Wang*, Gambogic acid-induced G2/M phase cell-cycle arrest via disturbing CDK7-mediated phosphorylation of CDC2/p34 in human gastric carcinoma BGC-823 cells. Carcinogenesis, 2007, 28:632-638.
(2) F. Wang, H. Zhang, X. Zhang, Y. Wang, F. Ren, Y. Zhai, and Z. Chang*, Varp interacts with Rab38 and functions as its potential effector. Biochem Biophys Res Commun, 2008, 372:162-167.
(3) L. Yang, H.W. Zhang, R. Hu, Y. Yang, Q. Qi, N. Lu, W. Liu, Y.Y. Chu, Q.D. You, Q.L. Guo*, Wogonin induces G1 phase arrest through inhibiting Cdk4 and cyclin D1 concomitant with an elevation in p21Cip1 in human cervical carcinoma HeLa cells, Biochem Cell Biol, 2009, 87:933-942.
(4) Y. Wu, Y. Zhang, H. Zhang, X. Yang, Y. Wang, F. Ren, H. Liu, Y. Zhai, B. Jia, J. Yu, Z. Chang*, p15RS attenuates Wnt/{beta}-catenin signaling by disrupting {beta}-catenin.TCF4 Interaction, J Biol Chem, 2010, 285:34621-34631.
(5) L. Qiang, T. Wu, H.W. Zhang, N. Lu, R. Hu, Y.J. Wang, L. Zhao, F.H. Chen, X.T. Wang, Q.D. You, Q.L. Guo*. HIF-1alpha is critical for hypoxia-mediated maintenance of glioblastoma stem cells by activating Notch signaling pathway, Cell Death Differ, 2012, 19:284-294.
（6）Wang, E., Wang, D., Li, B., Ma, H., Wang, C., & Guan, L., Zhang, H., Yi, L. (2017). Capn4 promotes epithelial-mesenchymal transition in human melanoma cells through activation of the wnt/β-catenin pathway. Oncology Reports, 37(1), 379.